Harvard Business Review

NOVEMBER 9, 2011

COOs are relatively common in service industries such as financial services, energy, information technology and telecommunications, but in manufacturing sectors — such as automotive, chemical, and pharmaceutical companies — they are relatively rare.

COO 12

COO Sample Telecommunications Automotive 12

Harvard Business Review

SEPTEMBER 10, 2013

In the 1990s and 2000s, for example, several corporate-venture initiatives helped pharmaceutical companies catch up with rapid advances in bioscience that were threatening to undermine the value of their well-established expertise. Finance Innovation' Recognition is a powerful reward too. Executing on Innovation An HBR Insight Center.

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

In the 1990s and 2000s, for example, several corporate-venture initiatives helped pharmaceutical companies catch up with rapid advances in bioscience that were threatening to undermine the value of their well-established expertise. Finance Innovation Insight Center_Innovation no-intromercial' Recognition is a powerful reward too.

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Chartered Management Institute

FEBRUARY 26, 2024

Our lives are full of multiple interdependent decisions as we try to navigate complex interactions with multiple competing goals. Since founding the Human Diver in 2016, Gareth has given risk training to a wide variety of organisations, from oil and gas and construction to pharmaceuticals and software.

Uncertainty 52

Uncertainty Risk Management Training Compliance 52

Harvard Business Review

APRIL 5, 2012

The business had ambitious revenue growth goals, and sales leaders wanted to focus sales efforts on the most attractive opportunities. Incentive compensation, goal setting, and recognition. They can set territory sales goals that are challenging, attainable, and fair to all. Market potential adds insight to sales planning.

Retail 9

Retail Incentives Tactics Pharmaceuticals 9

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. Another problem we’ve seen is that some providers, seeking to fit in to a payment cycle, focus on short-term results, losing sight of the end goals. ” Health care.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

JUNE 16, 2016

Pharmaceutical companies spend millions upon millions preparing meticulous plans for new drug launches – and yet their route-to-market strategies haven’t changed in decades, even though the reality of the market has. The failure stemmed from resistance in the U.S. What builds management perspectives?

Planning 8

Planning Competitive Intelligence Pharmaceuticals Brand 8

Harvard Business Review

MAY 1, 2013

Without adequate financing, ministries of health and even private hospitals in developing countries often don''t have the resources needed to purchase diagnostic equipment, train workers, and ensure access to appropriate treatment. Three people die every minute from tuberculosis — a treatable and largely preventable disease.

Health Care 8

Health Care ROI NGO Long-term 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 13, 2011

You either achieve your goals or you don't. Here are some common examples: When pharmaceutical companies announce that a new drug has been "approved," they are actually saying that their researchers made some breakthrough discoveries as far back as fifteen years ago. Most organizations take the same stance.

Short-term 14

Short-term Pharmaceuticals Long-term Maturity 14

Harvard Business Review

DECEMBER 12, 2018

And new approaches to philanthropy, often termed impact investing , have emerged as a path to meet their goals. In this approach, drug discovery is developed around a specific disease and is financed by the efforts of a disease-focused foundation. Andrew Lo, a finance professor at MIT, has been a trailblazer in this area.

Pharmaceuticals 8

Pharmaceuticals Venture Funding Finance Development 8